The sense of well-being is central to the concept of quality of life (
QoL), but there is not a universally accepted definition of health-rel
ated QoL. QoL refers to the patient's own evaluation of the impact of
the disease. It includes physical, psychological and socioeconomic dim
ensions, and its measurement is of paramount importance in evaluating
research outcomes and in cost-benefit analyses. In addition, QoL asses
sment helps to identify problems and may be essential in chronic and d
isabling diseases such as in Parkinson's disease (PD). There are numer
ous reasons for the decrease in QoL suffered by PD patients: restricti
ons in mobility. falls, emotional disorders, social embarrassment, iso
lation, sleep disturbances, dyskinesias, and fluctuations. Many aspect
s of these disorders go unnoticed in clinical evaluation, and only QoL
assessment allows them to be rated. Generic instruments have been use
d in a few studies measuring QoL in PD patients. Only recently have sp
ecific instruments as PDQ-39 and PDQL-37 been designed and validated.
QoL assessment in PD is an important and expanding area, with a promis
ing application in clinical trials and pharmacoeconomics.